Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true figure may be higher, as the symptoms develop slowly and thus may go ...

The Acromegaly Consensus Group considered many of the advances that have occurred in the management of acromegaly over the past 10 years. First, the growth hormone receptor antagonist pegvisomant ...

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

The various surgical and radiologic methods of treating acromegaly have dramatically improved over the past 75 years. In addition to the improvements in primary surgical and radiation methods ...

Crinetics (CRNX) announced that the European Medicines Agency has validated the marketing authorization application for paltusotine, the first ...

Acromegaly is due to hypersecretion of growth hormone and insulin-like growth factor I (IGF-I). The aim of treatment is to limit this excess secretion and to reduce morbidity and mortality.

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...

AIP (Aryl Hydrocarbon Receptor Interacting Protein) is the name of the gene which causes pituitary adenomas in some families with acromegaly and occasionally prolactinomas, and very rarely with other ...